Abstract
We assessed the impact of long-term fluvastatin treatment on adverse atherosclerotic cardiac events (cardiac death, myocardial infarction, and revascularization excluding repeat interventions due to restenosis in the first 6 months) in 847 patients (fluvastatin [n = 417] or placebo [n = 430]) with average cholesterol levels treated with stents in the Lescol Intervention Prevention Study (LIPS). During the 4-year follow-up period, fluvastatin significantly decreased total cholesterol and low-density lipoprotein cholesterol levels and decreased the risk of first adverse atherosclerotic cardiac events by 30% compared with placebo (95% confidence interval -49 to -3.4, p = 0.03).
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Anticholesteremic Agents / administration & dosage
-
Anticholesteremic Agents / therapeutic use*
-
Brazil
-
Canada
-
Cholesterol / blood
-
Cholesterol, HDL / blood
-
Cholesterol, LDL / blood
-
Coronary Artery Disease / blood
-
Coronary Artery Disease / diagnostic imaging
-
Coronary Artery Disease / pathology
-
Coronary Artery Disease / therapy*
-
Drug Administration Schedule
-
Europe
-
Fatty Acids, Monounsaturated / administration & dosage
-
Fatty Acids, Monounsaturated / therapeutic use*
-
Female
-
Fluvastatin
-
Humans
-
Indoles / administration & dosage
-
Indoles / therapeutic use*
-
Longitudinal Studies
-
Male
-
Middle Aged
-
Myocardial Infarction / mortality
-
Myocardial Infarction / prevention & control*
-
Myocardial Revascularization*
-
Radiography
-
Severity of Illness Index
-
Stents*
-
Treatment Outcome
-
Triglycerides / blood
Substances
-
Anticholesteremic Agents
-
Cholesterol, HDL
-
Cholesterol, LDL
-
Fatty Acids, Monounsaturated
-
Indoles
-
Triglycerides
-
Fluvastatin
-
Cholesterol